Anti stambpl1

American Type Culture Collection (Manassas, VI, USA) supplied all cell lines, and cells were cultured in Dulbecco’s modified Eagle’s medium consisting of 10% fetal bovine serum, 5% penicillin–streptomycin antibiotic, and 100 μg/mL gentamycin. R&D (Minneapolis, MN, USA) supplied the recombinant human TRAIL, z-VAD, and anti-survivin antibodies. Anti-Mcl-1, anti-STAMBPL1, anti-USP53, and DR5 siRNA was purchased from Santa Cruz Biotechnology (Dallas, TX, USA), and Cell Signaling Technology (Beverly, MA, USA) supplied the anti-PARP-1, anti-Bcl-2, anti-Bcl-xL, anti-caspase-3, anti-cIAP1, anti-c-FLIP, and anti-DR5 antibodies. Anti-DR4 antibody was obtained from Abcam (Cambridge, MA, USA). BD Biosciences (San Jose, CA, USA) supplied the anti-Bim and anti-XIAP antibody. STAMBPL1 plasmid was provided by Dr. Eek-Hoon Jho (University of Seoul, Seoul, Korea). Control (GFP) siRNA was purchased from Bioneer (Daejeon, Korea). Anti-actin antibody and all other reagents were supplied by Sigma Chemical Co. (St. Louis, MO, USA).

Sigma Chemical Co. provided honokiol, cycloheximide and MG132 (St. Louis, MO, USA), and R&D system supplied recombinant human recombinant TRAIL and z-VAD-fmk (Minneapolis, MN, USA). Enzo Life Sciences provided lactacystin (Ann Arbor, MI, USA). The primary antibodies were as follows: Cell Signaling Technology supplied anti-PARP, anti-cleaved caspase-3, anti-Bcl-xL, anti-DR5, anti-CHOP, and anti-UCHL1 (Beverly, MA, USA). Sigma Chemical Co. supplied anti-actin (St. Louis, MO, USA). Enzo Life Sciences provided anti-pro-caspase-3 and anti-c-FLIP (San Diego, CA, USA). BD Biosciences provided anti-Bim and anti-XIAP (San Jose, CA, USA). Abcam supplied anti-DR4 (Cambridge, MA, USA). R&D system supplied anti-survivin (Minneapolis, MN, USA). Santa Cruz Biotechnology provided anti-Mcl-1, anti-Bcl-2, anti-cIAP2, anti-ATF4, anti-Ub, anti-Cbl, anti-Itch, anti-USP14, anti-USP33, anti-OTUB1, anti-TRABID, and anti-STAMBPL1 (St. Louis, MO, USA). Bethyl Laboratories Inc provided anti-USP7 and anti-USP8 (Montgomery, TX, USA). Novus Biologicals supplied anti-USP53 (Centennial, CO, USA). Abnova provided anti-USP9X (Taipei City, Taiwan). The siRNAs were as follows: GFP (control) siRNA (Bioneer, Daejeon, Korea), DR5 siRNA (Invitrogen, Carlsbad, CA, USA), and STAMBPL1 siRNA (Santa Cruz Biotechnology, St. Louis, MO, USA). STAMBPL1 plasmid was a gift from Dr. H.C. Kang (Ajou University, Suwon, Korea).